Introduction
============

The overall prevalence of hypertension among adults is about 35%, since the prevalence of hypertension increases with age, from 40% of middle-aged individuals and up to 68% of elderly individuals.[@b1-ppa-8-1683]--[@b3-ppa-8-1683] It is a growing public health problem in Western countries with aging populations.[@b4-ppa-8-1683] Most population-based studies confirm that hypertension increases the risk for cardiovascular events.[@b5-ppa-8-1683] Antihypertensive (AHT) agents can effectively lower blood pressure (BP) and significantly reduce the rates of stroke, coronary heart disease, cardiovascular death, and total mortality by 30%--40%, 20%--21%, 26%--28%, and 13%--16%, respectively.[@b6-ppa-8-1683]

Hypertension, however, remains difficult to control, with BP control achieved by only 40% of hypertensive patients in primary care.[@b7-ppa-8-1683] The failure of physicians to intensify therapy (clinical inertia) and low adherence by patients to medication are considered the major modifiable causes of poor BP control.[@b8-ppa-8-1683],[@b9-ppa-8-1683] Adherence can be defined as the extent to which patients follow the instructions they are given for prescribed treatments. About 30%--50% of patients show low adherence to AHT,[@b10-ppa-8-1683],[@b11-ppa-8-1683] and poor adherence is associated with higher BP.[@b12-ppa-8-1683]

A report by the World Health Organization, addressing the general importance of improving adherence to long-term medical treatments, found that adherence resulted from complex interactions among the social environment, patients, and health care professionals.[@b13-ppa-8-1683] Low adherence has also been reported to increase the cost of treating hypertension by 15%--20%, and to be associated with more frequent hospitalization, use of emergency services, and admission to intensive care.[@b14-ppa-8-1683]

Low adherence to long-term treatment often occurs when the treatment is complex or when the disease is asymptomatic. Low adherence to AHT reduces drug effectiveness and increases the risk of cardiovascular morbidities. Conversely, adherence to AHT has been reported to reduce the risk of hospitalization by about 50% and to reduce mortality rates.[@b15-ppa-8-1683],[@b16-ppa-8-1683]

Several factors have been reported associated with poor adherence to AHT, including patient perception that the disease is not significant, forgetfulness, the occurrence of adverse drug effects, lack of treatment effectiveness, and the patient's poor or incomplete knowledge of the disease.[@b17-ppa-8-1683],[@b18-ppa-8-1683] Most of these factors related to non-adherence, however, are modifiable and previous trials have shown that several strategies are effective in improving adherence to AHT.[@b19-ppa-8-1683] However, most clinical trials failed to evidence improvements in lowering BP.

The aim of the study was to evaluate the effectiveness of a multifactorial intervention based on a nurse-led motivational interview, simplification of dosing regimen by a pharmacist, reminder packaging, social and family support, and BP self-measurement intervention in reducing systolic and diastolic BP in patients with elevated BP.

Methods and design
==================

Study design
------------

This study was a two arm, parallel, multicenter, randomized controlled trial performed in three regions of Spain (the Balearic Islands, Aragon, and Catalonia) between February 2011 and September 2013. The study was approved by the Research Ethics Committee of the Balearic Islands (Mallorca, Spain). The study design, procedures and reporting followed the CONSORT statement recommendations on randomized controlled trials.[@b20-ppa-8-1683]

Participants and randomization
------------------------------

Participating nurses were selected from 28 primary care centers. Patients aged 18--80 years with uncontrolled essential hypertension, as defined by European Societies of Hypertension and Cardiology (ESH/ESC) guidelines[@b21-ppa-8-1683] (ie, systolic BP ≥140 mmHg and/or average diastolic BP ≥90 mmHg in patients without diabetes type II or renal failure, or ≥130/80 mmHg for patients with diabetes type II or renal failure, on two consecutive visits 2 weeks apart), and attending a nurse consultation, were deemed eligible. Patients with non-essential hypertension; those undergoing hemodialysis; institutionalized or terminally ill patients; and those unwilling to provide informed consent were excluded. Patients were enrolled in the study from February 2011 to August 2012.

Randomization and allocation concealment were centralized at a single coordinating center, using a computer generated allocation sequence with a block size of eight. Once participants had provided verbal and written informed consent, they were randomized to either the intervention or the control group.

### Sample size

Sample size was calculated based on an expected mean difference of 6 mmHg and a standard deviation (SD) of 15 mmHg. The calculation was also based on a conservative assumption of 15% contamination in the control group and loss to follow-up of 20% of patients. Based on these calculations, we planned to enroll 320 patients.

Blinding
--------

Due to study procedures, patients and nurses could not be blinded to the patient allocation. The main outcome was assessed by an external nurse not involved in the study and blinded to patient allocation. The statistician and the physicians treating the patients were also blinded to patient allocation.

Multifactorial intervention
---------------------------

The intervention consisted of five components delivered during three interventional visits: (1) A motivational interview based on the Health Belief Model[@b22-ppa-8-1683] was designed to explore non-adherence to AHT treatment, to resolve ambivalences that patients had regarding medication, and to explore perceptions that patients had about their ability to control events (locus of control). (2) Pillbox reminder: a 7-day pillbox organizer was provided to each patient and its use explained. (3) Family support: each patient was allowed to designate one person in his/her household who would be responsible for reminding the patient to take medication and would monitor medication intake. The designated person was required to accept responsibility for these tasks. (4) BP measurements and AHT reminder forms: each patient was provided 12 forms (one per month) to record the date, hour, and results of all BP measurements. AHT dosage and a telephone contact number were recorded on each form. This information was frequently updated. (5) Simplification of dosing regimen*:* AHT treatment was recorded at the baseline visit. A pharmacist supervised each patient's dosage and treatment and, when possible, simplified the dosing regimen at the first follow-up visit.

The first follow-up visit took place after 1 month and consisted of a motivational interview (25 minutes), simplification of dosing regimen, and instructions on a pill reminder (5 minutes), self-recording of BP (5 minutes), and family support (5 minutes). The second and third visits took place after 3 and 9 months, respectively, each consisting of a motivational interview (25 minutes), check of self-recorded BP (5 minutes), and family support (5 minutes).

Control group
-------------

Patients randomized to the control group did not receive any change in their care. However, they were contacted at baseline and at 12 months and asked to complete the same measurements and interviews as the intervention group.

### Data collection and management

Patients in both groups had two baseline visits 1 week apart and before study initiation to ensure that they met study criteria. Data were obtained at the second baseline visit and at 12-month follow-up from patient interviews and reviews of primary care records.

Parameters recorded at baseline included BP, age, sex, weight, height, marital status, social class, level of education, hypertension duration, number of AHT drugs taken, adherence to AHT treatment, cardiovascular risk factors, target organ damage, cardiovascular diseases, nephropathy, and cardiovascular risk. BP, adherence to AHT treatment, and changes in AHT medication were recorded at 12 months.

Social class was assessed according to the guidelines of the Spanish National Occupational Classification 2011.[@b23-ppa-8-1683] Duration of hypertension was calculated from the year of diagnosis in primary care records; patients with grade III or severe hypertension were defined as those with BP ≥180/110 mmHg, as determined by European Guidelines.

Patient adherence to medication at baseline was assessed retrospectively by determining medication refills and medication possession ratio during the previous 6 months of a randomly chosen AHT drug. The medication possession ratio was defined as the number of days' supply of medication dispensed divided by the number of days evaluated.

Hypercholesterolemia was defined as a total cholesterol concentration ≥250 mg/dL, a low-density lipoprotein-cholesterol concentration ≥155 mg/dL or a high-density lipoprotein-cholesterol concentration \<40 mg/dL in men and \<48 mg/dL in women or treatment with lipid-lowering drugs. Diabetes mellitus type II was defined as a fasting plasma glucose concentration ≥126 mg/dL, a 2-hour-post-load plasma glucose concentration ≥200 mg/dL, or treatment with AHA agents. Smoking was defined as currently smoking cigarettes and obesity as a body mass index ≥30 kg/m^2^. A family history of premature cardiovascular disease was defined as a male or female first-degree relative experiencing a cardiovascular event before age 55 or 65 years, respectively.

Microalbuminuria and elevated serum creatinine concentrations were considered surrogates for target organ damage. Microalbuminuria was defined as urinary excretion of 30--300 mg/dL albumin and elevated serum creatinine as a concentration of 1.3--1.5 mg/dL in men and 1.2--1.4 mg/dL in women. Patients were also assessed for nephropathy and left ventricular hypertrophy as detected in a positive echocardiogram.

A history of cardiovascular disease included stroke, ischemic heart disease, and/or congestive heart failure.

The REGICOR tables are the calibration of Framingham's equation in a Spanish population. These tables estimate the risks of coronary morbidity and mortality in individuals aged 35--74 years, differentiate diabetic from non-diabetic patients and include measures of high-density lipoprotein-cholesterol concentration.[@b24-ppa-8-1683]

Changes in AHT medication at 12 months were determined by reviewing each patient's electronic drug recorder. The total number of changes included changes in dosage and active drugs. Patient adherence to medication was based on the medication possession ratio during the 6 months prior to enrollment and the final visit.

Primary and secondary outcomes
------------------------------

The primary outcome measure was systolic BP at 12 months. BP was measured according to ESH/ESC guidelines using an OMROM 705 CP automated sphygmomanometer with a printer. Final data at 12 months were collected by independent research personnel not involved in the performance of the trial and blinded to patient allocation.

### Secondary outcome measures

Secondary outcomes included diastolic BP at 12 months and proportion of participants with adequate BP control at 12 months according to ESH/ESC guidelines.

Statistical analysis
--------------------

Outcomes were analyzed on an intention-to-treat basis. Categorical variables were reported as numbers and percentages and continuous variables as medians and interquartile ranges. Categorical baseline variables were compared using Fisher's exact test or the chi-squared test. Continuous baseline variables were compared using Student's *t*-test.

The unadjusted effectiveness of the intervention was estimated using Student's *t*-test. Since clinical inertia may be an important confounder for the effect of the intervention, the protocol included adjustments for changes in AHT treatment during the study. The total number of changes in treatment was assessed at follow-up and the effectiveness of the intervention was adjusted by means of a generalized linear model based on the normal distribution of the primary outcome and the identity link function.

Relative risks (RR) were calculated based on the proportion of patients in the intervention group with BP control. The absolute risk reduction and number needed to treat were also calculated from the RR.

There were no relevant missing data ([Figure 1](#f1-ppa-8-1683){ref-type="fig"}), with only 14 of 223 (6.6%) patients missing the final evaluation. Based on an intention-to-treat analysis, these 14 patients were assigned a basal BP at 12 months.

Statistical significance was set at 5%. Stata version 11.0 (StataCorp, College Station, TX, USA) was used for analyses.

Results
=======

Patient characteristics
-----------------------

[Table 1](#t1-ppa-8-1683){ref-type="table"} shows that patient characteristics at baseline were similar in the two groups. Overall, mean patient age was 65 years (SD =10.7 years), 56% were men and 75.8% were adherent to medication. The median number of risk factors was 2 (interquartile range: 1--3), the mean duration of hypertension was 7 years (SD =6 years), and 20 patients were diagnosed with hypertension the year before enrollment. The median number of AHT drugs per patient was 2 (interquartile range: 1--3), with 26.9% of patients receiving one agent. Of the 73.1% of patients taking ≥2 drugs, 70% were taking fixed-dose combinations in a single pill. Angiotensin-converting enzyme inhibitors (ACEI; 19.3%), diuretics (14.7%), and calcium channel blockers (CCB; 14.1%) were the drugs most frequently prescribed as monotherapy, followed by beta-blockers (11.3%), angiotensin II receptor antagonists (ARBII) (10.5%), and alpha-blockers (3.6%). In combination, the drugs most frequently prescribed were an ARBII plus a diuretic (12.9%); an ACEI plus a diuretic (6.4%); an ACEI plus a CCB (4.9%); an ARBII, a diuretic, plus a CCB (0.8%); and an ACEI, a CCB plus a diuretic (0.3%).

The REGICOR Score is used to estimate risk in individuals aged 35--75 years; since 36 patients (17%) were over 75-years old, their REGICOR Score could not be determined. The mean risk of cardiovascular disease at 10 years was 1.5% (SD =0.7%).

The application of the different components of the multifactorial intervention varied widely. Dose regimens were simplified in six patients (5.7%); 70 patients (66.7%) participated in all three motivational sessions; pill reminders were provided to 46 patients (43.8%); filled BP measurement forms were submitted by 55 patients (52.4%) each at visits one and two, and by 33 patients (31.4%) at visit three; and 51 patients (48.6%) designated a person to remind them and supervise adherence to treatment.

Adherence to AHT medication at 12 months was 76%, 75.3% in the intervention group, and 76.7% in the control group. At 12 months, 51.4% in the intervention group versus 50.8% in the control group were below 80% adherence.

Outcomes
========

Primary outcome
---------------

Efficacy results are shown in [Table 2](#t2-ppa-8-1683){ref-type="table"}. Systolic BP at 12 months was similar in the intervention and control groups (151.3 mmHg versus 153.7 mmHg, *P*=0.294), as were the reductions from baseline (5 mmHg versus 2.1 mmHg).

Secondary outcomes
------------------

Diastolic BP at 12 months was similar in the intervention and control groups (83.4 mmHg versus 83.6 mmHg), as was the percentage in each group who achieved BP control according to ESC/ESH guidelines (15.8% \[18/114\] versus 9.2% \[10/109\], *P*=0.098). Relative to the control group, the RR of achieving BP control in the intervention group was 1.72 (95% confidence interval \[CI\]: 0.83--3.56), with a RR reduction of −0.72 (95% CI: −2.56 to 0.17) and an absolute risk reduction of −0.07% (95% CI: −0.15% to 0.02%). Consequently, 15 patients would have to receive the proposed interventions for 1 year for one patient to achieve BP control when compared with patients receiving usual care.

Conclusion
==========

The main finding of our study was that a multifactorial intervention based on improving treatment adherence in a primary care setting did not lead to the expected improvement in BP. Similar to previous findings, we found that adherence to treatment tends to be poorer in populations with poorly controlled BP.[@b25-ppa-8-1683] Moreover, patient adherence to medication varied greatly when treatment was supervised by the medical staff,[@b26-ppa-8-1683] with the percentage of patients adherent at the end of follow-up varying from 53.2%--94.5%. This wide adherence variability may be due to the characteristics of nurses and the method of delivery of the intervention. Our results suggest that differences in the application of the intervention and overestimation of its effects may have resulted in the absence of statistically significant differences between our intervention and control groups. Alternatively, few treatments were able to be simplified, since most of the patients were taking two or three drugs at enrollment, with most taking medications once per day. Indeed, only six patients experienced changes in medication over the 12-month study period.

Our findings are nevertheless consistent with previous results.[@b27-ppa-8-1683]--[@b30-ppa-8-1683] For example, a study of hypertensive patients with diabetes type II and kidney disease testing a multifactorial intervention that included self-BP monitoring, a revision of the medication, telephone calls, and motivational interviews, found that this intervention did not significantly improve systolic or diastolic BP. A pilot study testing the ability of behavioral feedback to improve medication adherence in older adults with hypertension found that this intervention improved adherence, but not systolic BP. Similarly, motivational interviews in African-American patients improved adherence, but not systolic BP, and simplification of AHT regimens was also ineffective. In contrast, the Com99[@b31-ppa-8-1683] trial, which tested a brief adherence-based intervention in a large number of patients, found that the intervention significantly reduced systolic BP, by a mean 2 mmHg, compared with a control group.

Clinical inertia is one of the most important modifiable factors related to lack of BP control. Moreover, changes in AHT regimens have been associated with improvements in systolic and diastolic BP. Our study hypothesized that clinical inertia could be an important confounder, especially if general practitioners (GPs) overseeing patients in the intervention group were more prone to change AHT treatment than GPs of control patients. Thus, to minimize the possibility of differential effects between groups, GPs were blinded to patient allocation, and all changes in AHT regimens were registered in both groups. After adjusting for changes in treatment, the adjusted and unadjusted results did not significantly differ.

The strength of this study is the use of a methodology designed to minimize the confounding effect of clinical inertia. The trial design showed great external validity, since only 14 patients were lost to follow-up and both adherence to medication and systolic BP were measured objectively and in a blinded manner.

This study had several limitations. Similar to most behavioral interventions, blinding is often difficult to achieve due to the nature of these interventions. However, efforts were made to determine the final outcome measurements and the allocation of patients to the GPs in a blinded manner. Although our study design included a specific feature to prevent Hawthorne effects (ie, preventing or hampering control patients from attending follow-up visits),[@b32-ppa-8-1683] we cannot exclude the possibility that the level of care in the control group was positively influenced by participation in the trial.
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###### 

Baseline demographic and clinical characteristics in the control and intervention groups

  Baseline characteristics                                                          Control group n/N (%)   Intervention group n/N (%)   *P*-value
  --------------------------------------------------------------------------------- ----------------------- ---------------------------- -----------
  Age[\*](#tfn1-ppa-8-1683){ref-type="table-fn"}                                    66.7±11.7               64.5±9.8                     0.145
  Men                                                                               55/102 (53.9)           62/105 (59.0)                0.485
  Marital status                                                                                                                         
   Married/cohabiting                                                               61/101 (60.4)           67/105 (63.8)                
   Single/divorced/widowed                                                          40/101 (39.6)           38/105 (36.2)                0.667
  Level of education                                                                                                                     
   None                                                                             23/107 (21.5)           21/114 (18.4)                
   Elementary school                                                                58/107 (54.2)           62/114 (54.4)                
   Middle or high school                                                            17/107 (15.9)           18/114 (15.8)                
   University studies                                                               9/107 (8.4)             13/114 (11.4)                0.859
  Social class                                                                                                                           
   Class I--II                                                                      3/76 (3.9)              3/81 (3.7)                   
   Class III                                                                        53/76 (69.7)            64/81 (79.0)                 
   Class IV--V                                                                      20/76 (26.3)            14/81 (17.3)                 0.380
   SBP, mmHg[\*](#tfn1-ppa-8-1683){ref-type="table-fn"}                             155.5±13.4              156.3±15.1                   0.697
   DBP, mmHg[\*](#tfn1-ppa-8-1683){ref-type="table-fn"}                             83.6±10.3               84.7±10.7                    0.436
   Baseline heart rate, bpm[\*](#tfn1-ppa-8-1683){ref-type="table-fn"}              75.1±13.5               76.0±14.5                    0.645
   Severe hypertension                                                              4/104 (3.8)             7/105 (6.7)                  0.361
   Hypertension duration (years)[\*](#tfn1-ppa-8-1683){ref-type="table-fn"}         7.0±5.9                 6.3±6.2                      0.517
   No of AHT drugs at baseline[\*](#tfn1-ppa-8-1683){ref-type="table-fn"}           2.3±1.1                 2.3±1.2                      0.754
   Baseline adherence to AHT treatment[\*](#tfn1-ppa-8-1683){ref-type="table-fn"}   76.49±30.9              75.14±26.2                   0.789
  Cardiovascular risk factors                                                                                                            
   Cigarette smoking                                                                16/104 (15.4)           21/105 (20)                  0.532
   Hypercholesterolemia                                                             57/104 (54.8)           61/105 (58.1)                0.632
   Diabetes mellitus                                                                48/104 (46.2)           53/105 (50.5)                0.532
   Obesity (BMI \>30 kg/m^2^)                                                       52/104 (50)             62/105 (59)                  0.189
   Family history of premature CHD                                                  5/104 (4.8)             8/105 (7.6)                  0.400
  Target organ damage                                                                                                                    
   Left ventricular hypertrophy                                                     0/104 (0)               3/105 (2.4)                  0.08
   Microalbuminuria                                                                 4/104 (3.8)             2/105 (1.9)                  0.401
   Elevated serum creatinine                                                        5/104 (4.8)             4/105 (3.8)                  0.722
   Nephropathy                                                                      9/105 (8.6)             5/104 (4.8)                  0.260
  Cardiovascular diseases                                                                                                                
   Stroke                                                                           3/104 (2.9)             2/105 (1.9)                  0.643
   Ischemic heart disease                                                           5/104 (4.8)             9/105 (8.6)                  0.276
   Congestive heart failure                                                         5/104 (4.8)             6/105 (5.7)                  0.769
   REGICOR cardiovascular risk                                                      1.46 (0.6)              1.52 (0.74)                  0.582

**Note:**

Data are expressed as mean ± standard deviation.

**Abbreviations:** n, sample; N, population; BMI, body mass index; CHD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; AHT, antihypertensive; REGICOR, Registre Gironí del cor.

###### 

Blood pressure measures in the control and intervention groups at 12 months

  Efficacy                                                           12 months                                                           
  ------------------------------------------------------------------ -------------- -------------- ------- -------------- -------------- -------
  SBP, mmHg, mean (SD)                                               153.7 (16.8)   151.3 (17.8)   0.294   153.8 (0.70)   151.3 (0.54)   0.290
  DBP, mmHg, mean (SD)                                               83.6 (11.4)    83.4 (11.1)    0.917   83.6 (0.71)    83.5 (0.62)    0.901
  ΔSBP, mmHg, mean (SD)[\*](#tfn4-ppa-8-1683){ref-type="table-fn"}   −2.1 (16.8)    −5 (18.3)      0.208   −2.1 (1.58)    −5.1 (1.71)    0.219
  ΔDBP, mmHg, mean (SD)[\*](#tfn4-ppa-8-1683){ref-type="table-fn"}   −0.1 (9.1)     −1.2 (9.1)     0.405   −0.16 (0.43)   −1.19 (0.47)   0.515

**Note:**

Adjusted for changes in AHT medication over time.

Δ represent changes in SBP and DBP between the baseline value and the 12 months value.

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; AHT, antihypertensive.
